Arrowstreet Capital
CBIO

Arrowstreet Capital’s Crescent Biopharma CBIO Stock Holding History

Arrowstreet Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-352
Closed -$108K – 2378
2020
Q3 		$108K Sell
352
-494
-58% -$189K ﹤0.01% 2246
2020
Q2 		$318K Sell
846
-440
-34% -$125K ﹤0.01% 2088
2020
Q1 		$293K Sell
1,286
-1,510
-54% -$577K ﹤0.01% 1653
2019
Q4 		$1.48M Buy
+2,796
New +$1.51M ﹤0.01% 1231

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital's CBIO Position: Q4 2020 in Review

Arrowstreet Capital sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 352 shares — an estimated $108K sold.

Arrowstreet Capital first reported a position in CBIO in Q4 2019 and held it in 4 quarters. The position peaked at $1.48M in Q4 2019. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Arrowstreet Capital reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 352 Crescent Biopharma shares in Q4 2020, an estimated $108K.
  • Arrowstreet Capital first reported a position in Crescent Biopharma in Q4 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Crescent Biopharma position peaked at $1.48M in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.